Cross-Reactivity of Schistosoma mansoni Cytosolic Superoxide Dismutase, a Protective Vaccine Candidate, with Host Superoxide Dismutase and Identification of Parasite-Specific B Epitopes
暂无分享,去创建一个
R. Corrêa-Oliveira | P. LoVerde | E. Mathiowitz | Rosemary M. Cook | C. Carvalho-Queiroz | N. Egilmez | C. Wang | Nicola Bailey
[1] D. Taylor. Schistosome vaccines , 2005, Experientia.
[2] P. LoVerde,et al. Protection against Schistosoma mansoni utilizing DNA vaccination with genes encoding Cu/Zn cytosolic superoxide dismutase, signal peptide-containing superoxide dismutase and glutathione peroxidase enzymes. , 2003, Vaccine.
[3] J. Ježek,et al. Differences in immunogenicity and vaccine potential of peptides from Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase. , 2003, Vaccine.
[4] T. Nutman,et al. Class and subclass selection in parasite-specific antibody responses. , 2003, Trends in parasitology.
[5] Hongfan Sun,et al. Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. , 2003, Vaccine.
[6] J. Brewer,et al. Interleukin‐18 plays a role in both the alum‐induced T helper 2 response and the T helper 1 response induced by alum‐adsorbed interleukin‐12 , 2003, Immunology.
[7] N. R. Bergquist. Schistosomiasis: from risk assessment to control. , 2002, Trends in parasitology.
[8] Edward J. Pearce,et al. The immunobiology of schistosomiasis , 2002, Nature Reviews Immunology.
[9] D. Colley,et al. Practical and ethical issues in the development of a vaccine against schistosomiasis mansoni. , 2002, The American journal of tropical medicine and hygiene.
[10] D. Volkin,et al. Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres. , 2002, Journal of pharmaceutical sciences.
[11] M. Patarroyo,et al. Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres. , 2002, Vaccine.
[12] M. L. Mackichan,et al. Recent developments in adjuvants for vaccines against infectious diseases. , 2001, Biomolecular engineering.
[13] T. Wynn,et al. Defining a schistosomiasis vaccination strategy - is it really Th1 versus Th2? , 2000, Parasitology today.
[14] L. Chitsulo,et al. The global status of schistosomiasis and its control. , 2000, Acta tropica.
[15] R. Corrêa-Oliveira,et al. Natural versus drug-induced resistance in Schistosoma mansoni infection. , 2000, Parasitology today.
[16] M. Sabel,et al. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. , 2000, Cancer research.
[17] Brito,et al. CD4+ T Cells of Schistosomiasis Naturally Resistant Individuals Living in an Endemic Area Produce Interferon‐γ and Tumour Necrosis Factor‐α in Response to The Recombinant 14kdaSchistosoma mansoni Fatty Acid‐Binding Protein , 2000, Scandinavian journal of immunology.
[18] M. Michalak,et al. Fine specificity of autoantibodies to calreticulin: epitope mapping and characterization , 2000, Clinical and experimental immunology.
[19] Virander S. Chauhan,et al. Analysis of Immune Responses against T- and B-Cell Epitopes fromPlasmodium falciparum Liver-Stage Antigen 1 in Rodent Malaria Models and Malaria-Exposed Human Subjects in India , 2000, Infection and Immunity.
[20] C. Hunter,et al. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. , 1999, Journal of immunology.
[21] O’Hagan,et al. Microparticles and polymers for the mucosal delivery of vaccines. , 1998, Advanced drug delivery reviews.
[22] P. LoVerde. Do antioxidants play a role in schistosome host-parasite interactions? , 1998, Parasitology today.
[23] C. A. Santos,et al. Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model , 1998, Cancer Immunology, Immunotherapy.
[24] Scott D. Putney,et al. Improving protein therapeutics with sustained-release formulations , 1998, Nature Biotechnology.
[25] A. Butterworth. Immunological aspects of human schistosomiasis. , 1998, British medical bulletin.
[26] N. R. Bergquist. Schistosomiasis vaccine development: progress and prospects. , 1998, Memorias do Instituto Oswaldo Cruz.
[27] A. Deelder,et al. Anti-schistosome IgG4 and IgE at 2 years after chemotherapy: infected versus uninfected individuals. , 1997, The Journal of infectious diseases.
[28] P. LoVerde,et al. Schistosoma mansoni: the developmental regulation and immunolocalization of antioxidant enzymes. , 1997, Experimental parasitology.
[29] Donald E. Chickering,et al. Biologically erodable microspheres as potential oral drug delivery systems , 1997, Nature.
[30] J. Schwartz,et al. Expression and characterization of glutathione peroxidase activity in the human blood fluke Schistosoma mansoni , 1996, Infection and immunity.
[31] A. Simpson,et al. Evidence that cellular immune responses to soluble and membrane associated antigens are independently regulated during human schistosomiasis mansoni , 1996, Parasite immunology.
[32] P. LoVerde,et al. Immune response to Schistosoma mansoni phosphoglycerate kinase during natural and experimental infection: identification of a schistosome-specific B-cell epitope , 1995, Infection and immunity.
[33] H. Okada,et al. Biodegradable microspheres in drug delivery. , 1995, Critical reviews in therapeutic drug carrier systems.
[34] D. Engels,et al. Impact of repeated community-based selective chemotherapy on morbidity due to schistosomiasis mansoni. , 1994, The American journal of tropical medicine and hygiene.
[35] A. Sher,et al. Interferon-gamma production by peripheral blood mononuclear cells from residents of an area endemic for Schistosoma mansoni. , 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[36] D. Harn,et al. T and B epitope determination and analysis of multiple antigenic peptides for the Schistosoma mansoni experimental vaccine triose-phosphate isomerase. , 1994, Journal of immunology.
[37] James Sl,et al. Immune effector role of macrophages in experimental schistosomiasis mansoni. , 1994 .
[38] D. Boros,et al. Immune effector role of macrophages in experimental schistosomiasis mansoni. , 1994, Immunology series.
[39] E R James,et al. Superoxide dismutase. , 1994, Parasitology today.
[40] R. Maizels,et al. Immunological modulation and evasion by helminth parasites in human populations , 1993, Nature.
[41] M. Ouattara,et al. Resistance to Schistosoma mansoni in humans: influence of the IgE/IgG4 balance and IgG2 in immunity to reinfection after chemotherapy. , 1993, The Journal of infectious diseases.
[42] A. Vashishtha,et al. Surface-exposed conserved region of the streptococcal M protein induces antibodies cross-reactive with denatured forms of myosin. , 1993, Journal of immunology.
[43] P. Coulson,et al. Pulmonary granulomatous hypersensitivity: cell-mediated responses to embolized schistosome larvae and eggs. , 1993, Regional immunology.
[44] C. Shoemaker,et al. T and B cell epitope mapping of SM23, an integral membrane protein of Schistosoma mansoni. , 1992, Journal of immunology.
[45] D. Pritchard,et al. Immunity to helminths: Ready to tip the biochemical balance? , 1992, Parasitology today.
[46] M. Hammarskjöld,et al. Schistosoma mansoni: cloning of a complementary DNA encoding a cytosolic Cu/Zn superoxide dismutase and high-yield expression of the enzymatically active gene product in Escherichia coli. , 1992, Experimental parasitology.
[47] D. Dunne,et al. Human immunity to Schistosoma mansoni: observations on mechanisms, and implications for control. , 1992, Immunological investigations.
[48] A. Capron,et al. Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection , 1992, European journal of immunology.
[49] A. Capron,et al. Effector functions of eosinophils in schistosomiasis. , 1992, Memorias do Instituto Oswaldo Cruz.
[50] A. Prata,et al. Evidence for an association between human resistance to Schistosoma mansoni and high anti‐larval IgE levels , 1991, European journal of immunology.
[51] S. Davis,et al. Controlled release microparticles for vaccine development. , 1991, Vaccine.
[52] D. Rahman,et al. Biodegradable microparticles as controlled release antigen delivery systems. , 1991, Immunology.
[53] A. Simpson,et al. Human IgE, IgG4 and resistance to reinfection with Schistosomahaematobium , 1991, Nature.
[54] R. Prichard,et al. Schistosoma mansoni: levels of antioxidants and resistance to oxidants increase during development. , 1990, Experimental parasitology.
[55] M. Wright,et al. Comparison of the cloned genes of the 26- and 28-kilodalton glutathione S-transferases of Schistosoma japonicum and Schistosoma mansoni. , 1990, Molecular and biochemical parasitology.
[56] A. Sher,et al. The human immune response to defined immunogens of Schistosoma mansoni: elevated antibody levels to paramyosin in stool-negative individuals from two endemic areas in Brazil. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[57] D. Boros. Immunopathology of Schistosoma mansoni infection , 1989, Clinical Microbiology Reviews.
[58] R. Damian. Molecular mimicry: parasite evasion and host defense. , 1989, Current topics in microbiology and immunology.
[59] M. Wright,et al. Molecular and serological characteristics of the glutathione S‐transferases of Schistosoma japonicum and Schistosoma mansoni , 1988, Parasite immunology.
[60] R. Crouch,et al. Helminth anti-oxidant enzymes: a protective mechanism against host oxidants? , 1988, Parasitology today.
[61] R. Prichard,et al. Antioxidant systems in Schistosoma mansoni: evidence for their role in protection of the adult worms against oxidant killing. , 1988, International journal for parasitology.
[62] A. Sher,et al. Mechanisms of immune evasion in schistosomiasis. , 1987, Contributions to microbiology and immunology.
[63] J. Lambertucci,et al. Immune responses during human Schistosomiasis mansoni. XI. Immunologic status of patients with acute infections and after treatment. , 1985, Journal of immunology.
[64] A. Butterworth. Cell-mediated damage to helminths. , 1984, Advances in parasitology.
[65] A. Sher,et al. Mechanisms of protective immunity against Schistosoma mansoni infection in mice vaccinated with irradiated cercariae III. Identification of a mouse strain, P/N, that fails to respond to vaccination , 1983, Parasite immunology.
[66] A. Sher,et al. Mechanisms of protective immunity against Schistosoma mansoni infection in mice vaccinated with irradiated cercariae. IV. Analysis of the role of IgE antibodies and mast cells. , 1983, Journal of immunology.
[67] A. Sher,et al. Mechanisms of protective immunity against Schistosoma mansoni infection in mice vaccinated with irradiated cercariae. II. Analysis of immunity in hosts deficient in T lymphocytes, B lymphocytes, or complement. , 1982, Journal of immunology.
[68] S. T. Haralambides. Immunology of parasitic diseases. , 1980 .
[69] H. Towbin,et al. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[70] W. Lang. [The immunology of parasitic diseases]. , 1979, MMW, Munchener medizinische Wochenschrift.
[71] E. Ottesen,et al. Serological differences between acute and chronic schistosomiasis mansoni detected by enzyme-linked immunosorbent assay (ELISA). , 1979, The American journal of tropical medicine and hygiene.
[72] D. Colley,et al. Immune responses during human schistosomiasis mansoni. I. In vitro lymphocyte blastogenic responses to heterogeneous antigenic preparations from schistosome eggs, worms and cercariae. , 1977, International archives of allergy and applied immunology.
[73] N Katz,et al. A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni. , 1972, Revista do Instituto de Medicina Tropical de Sao Paulo.
[74] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.
[75] R. Taylor,et al. Studies on cyclic passage of yellow fever virus in South American mammals and mosquitoes; marsupials (Metachirus nudicaudatus and Marmosa) in combination with Aedes aegypti as vector. , 1948, The American journal of tropical medicine and hygiene.